Residency · Residency · Radiation Oncology

Thymic Malignancies: Postoperative Radiation and Dose Considerations

Overview

Thymic epithelial tumors are rare neoplasms located in the anterior mediastinum and include thymomas and thymic carcinomas. Thymomas tend to be relatively indolent, often demonstrating local invasion and pleural dissemination, but they rarely metastasize to distant sites. In contrast, thymic carcinomas exhibit more aggressive behavior, with higher rates of nodal involvement and distant metastasis. Surgery remains the primary treatment modality for these tumors, while the use of adjuvant radiation therapy is determined by factors such as the Masaoka staging system, the completeness of surgical resection, and the histologic subtype of the tumor. Additionally, paraneoplastic syndromes, particularly myasthenia gravis—which occurs in 30-50% of thymoma patients—play an important role in perioperative management.

Classification

WHO Histologic Classification

The World Health Organization classifies thymic epithelial tumors into several histologic types based on cellular morphology and behavior. Type A thymomas, also known as medullary thymomas, are composed of spindle cells and carry an excellent prognosis. Type AB thymomas are mixed tumors with a generally good prognosis. Type B1 thymomas resemble normal thymic cortex and also have a favorable outlook. Type B2 thymomas are cortical thymomas with a moderate prognosis. Type B3 tumors are well-differentiated thymic carcinomas with predominantly epithelial features and exhibit borderline behavior between thymomas and carcinomas. Finally, Type C tumors are classified as thymic carcinomas, which are aggressive and include variants such as squamous cell carcinoma, adenocarcinoma, or undifferentiated carcinomas.

Masaoka-Koga Staging System

The Masaoka-Koga system stages thymic tumors based on the extent of local invasion and metastasis. Stage I tumors are completely encapsulated with no microscopic capsular invasion. Stage IIA tumors show microscopic invasion through the capsule into surrounding fatty tissue, while Stage IIB tumors demonstrate macroscopic invasion into the capsule or mediastinal fat. Stage III tumors invade adjacent organs such as the lung, pericardium, or great vessels. Stage IVA is characterized by pleural or pericardial dissemination, and Stage IVB involves lymphogenous or hematogenous metastasis.

Indications for Adjuvant Radiation Therapy

Stage I (Complete Resection)

For completely resected Stage I thymomas, adjuvant radiation therapy is generally not recommended due to the very low risk of recurrence, which is less than 5%. Observation remains the standard approach in these cases.

Stage II (Complete Resection)

In Stage IIA disease, the role of adjuvant radiation therapy is controversial because the recurrence risk remains low, around 5-10%. Some institutions opt for observation, while others recommend adjuvant radiation. The International Thymic Malignancies Interest Group (ITMIG) consensus suggests that adjuvant radiation may be considered for Stage IIB tumors or those with invasive histologic subtypes such as B2 or B3. For Stage IIB thymomas, there is stronger consideration for adjuvant radiation, especially in cases with B2 or B3 histology. The typical radiation dose in these scenarios ranges from 45 to 50 Gy delivered in 25 fractions.

Stage III (Complete or Incomplete Resection)

Adjuvant radiation therapy is recommended for all Stage III thymomas following surgical resection. For patients with R0 resection (complete removal), doses of 50 to 54 Gy are advised. If microscopic residual disease remains (R1 resection), doses increase to 54 to 60 Gy, and for gross residual disease (R2 resection), doses range from 60 to 66 Gy. The radiation target includes the tumor bed, areas of adherence, and surgical clip locations.

Stage IVA (Pleural Dissemination)

The use of adjuvant radiation therapy in Stage IVA disease is controversial and technically challenging. In cases where debulking surgery achieves near-complete resection, hemithoracic pleural radiation therapy similar to that used in mesothelioma may be considered. The recommended dose is 45 to 50 Gy to the entire hemithorax, with an additional boost to any residual disease.

Thymic Carcinoma

Given the more aggressive nature of thymic carcinoma, adjuvant radiation therapy is indicated for all stages beyond Stage I. For Stage II and III thymic carcinoma, radiation doses of 54 to 60 Gy are recommended for R0 resections, and 60 to 66 Gy for R1 or R2 resections. Chemotherapy, typically cisplatin-based, should be considered in combination with radiation for advanced thymic carcinoma.

Unresectable Disease

For unresectable thymic tumors, definitive radiation therapy doses range from 60 to 70 Gy and are administered concurrently with chemotherapy regimens such as cisplatin/etoposide or CAP (cyclophosphamide, doxorubicin, cisplatin). An alternative approach involves neoadjuvant chemotherapy followed by surgery and adjuvant radiation for tumors that respond to induction therapy.

Radiation Therapy Technique

Target Volume Delineation

When residual disease is present, the gross tumor volume (GTV) is defined by visible tumor on postoperative CT or MRI. The clinical target volume (CTV) includes the preoperative tumor extent, which is delineated using fused preoperative imaging, surgical clips, and areas of adhesion to adjacent structures. Typically, the CTV is expanded by 1 to 2 cm from the tumor bed, respecting anatomic boundaries, and encompasses the entire thymic bed for more advanced tumors. For pleural-based recurrence patterns, especially in Stage III tumors, the ipsilateral pleural space may be included. The planning target volume (PTV) is created by adding a 5 to 7 mm margin to the CTV to account for respiratory motion and setup uncertainty. Respiratory motion management using 4D-CT is recommended for tumors exhibiting significant anteroposterior or craniocaudal movement.

Dose Prescriptions by Clinical Scenario

For R0 resection of thymoma, the prescribed dose is 45 to 50 Gy in 25 fractions. For R0 resection of thymic carcinoma, the dose is slightly higher at 50 to 54 Gy. In cases of R1 resection with microscopic positive margins, doses range from 54 to 60 Gy, while R2 resections with gross residual disease require 60 to 66 Gy. Definitive radiation for unresectable tumors is delivered at doses between 60 and 70 Gy.

Organs at Risk

Critical organs at risk (OAR) include the heart, bilateral lungs, esophagus, spinal cord, great vessels, trachea, and brachial plexus. The heart should receive a mean dose of 26 Gy or less, with V30 (volume receiving 30 Gy) limited to 46%, reflecting the anterior mediastinal location of thymic tumors which makes cardiac dose optimization essential. For the lungs, V20 should be kept at or below 35%, with a mean dose under 20 Gy. The esophagus mean dose should not exceed 34 Gy, and the spinal cord maximum dose should be limited to 45 Gy. Constraints for the great vessels, trachea, and brachial plexus vary by institution. In younger patients, who often have a long natural history of thymoma, minimizing the integral dose to all thoracic structures is important to reduce late toxicities.

IMRT/VMAT

Intensity-modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) is strongly recommended for anterior mediastinal tumors to optimize sparing of cardiac and pulmonary structures. While three-dimensional conformal radiation therapy (3D-CRT) using anterior-posterior/posterior-anterior fields with lateral boosts is feasible for simple target geometries, it generally provides inferior sparing of organs at risk. Proton therapy may offer dosimetric advantages for large anterior mediastinal tumors, particularly in young patients where long-term cardiac and pulmonary toxicity is a major concern.

Special Considerations

Myasthenia Gravis

Myasthenia gravis is present in 30-50% of patients with thymoma and requires careful perioperative management. Optimization of acetylcholinesterase inhibitors is essential, and intravenous immunoglobulin (IVIG) or plasmapheresis may be considered preoperatively. Although myasthenic crisis during or after radiation therapy is rare, it should be anticipated and managed accordingly. Thymectomy can improve or even cure myasthenia gravis in selected patients.

Recurrence Patterns

Thymoma recurrences are predominantly locoregional, often involving pleural dissemination or the local tumor bed. Distant metastases are uncommon in thymoma but more frequent in thymic carcinoma. Recurrences may occur many years after initial treatment, typically between 5 and 15 years, underscoring the need for long-term surveillance. For isolated recurrences, re-resection with or without re-irradiation may be considered.

Surveillance

Post-treatment surveillance typically involves chest CT scans every six months for the first two years, followed by annual imaging for at least ten years. Given the indolent nature of thymoma and the risk of late recurrence, some guidelines recommend lifelong annual imaging.

<image>An anterior coronal view of the mediastinum showing the thymus gland and its relationship to surrounding structures. A stage III thymoma is illustrated invading through the capsule into the pericardium and left lung. The postoperative CTV (blue shading) encompasses the thymic bed, areas of pericardial and lung adhesion, and surgical clip locations. Key organs at risk (heart, bilateral lungs, esophagus, great vessels) are labeled with dose constraint values.</image>

<image>A table-format summary of adjuvant radiation recommendations for thymic malignancies organized by Masaoka stage (rows: I, IIA, IIB, III, IVA, IVB) and completeness of resection (columns: R0, R1, R2, unresectable). Each cell contains the recommended dose range and whether RT is "not recommended," "consider," "recommended," or "strongly recommended." Thymic carcinoma recommendations are shown in a separate adjacent column with generally more aggressive dose recommendations at each stage.</image>

<image>An axial CT image at the level of the aortic arch showing an IMRT/VMAT dose distribution for adjuvant radiation after R1 resection of a stage III thymoma. The CTV (blue contour) is in the anterior mediastinum with the dose colorwash showing 54 Gy covering the target. The heart (red), bilateral lungs (cyan), and esophagus (green) are contoured with dose-volume histogram curves inset showing compliance with OAR constraints.</image>

Key Clinical Pearls

The Masaoka staging system and the completeness of surgical resection are the two most important factors guiding the need for adjuvant radiation therapy and the appropriate dose. Completely resected Stage I thymomas do not require radiation, whereas Stage III or incompletely resected tumors clearly benefit from adjuvant radiation. Thymoma has a prolonged natural history, with recurrences possible 10 to 15 or more years after initial treatment, necessitating long-term surveillance. Radiation-related late effects, including cardiac disease and secondary malignancies, must be carefully considered during treatment planning. Thymic carcinoma is biologically distinct from thymoma, behaving more aggressively; therefore, adjuvant radiation is recommended for essentially all stages beyond Stage I, with higher doses ranging from 54 to 66 Gy. Myasthenia gravis occurs in about one-third to one-half of thymoma patients and requires active perioperative management, although radiation therapy rarely precipitates myasthenic crisis. For large anterior mediastinal targets, advanced radiation techniques such as IMRT, VMAT, or proton therapy should be employed to minimize cardiac dose, especially in young patients who have a long expected survival after treatment.

References

• Detterbeck FC et al. "The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms." J Thorac Oncol. 2011;6(7 Suppl 3):S1710-S1716.
• Rimner A et al. "Postoperative radiation therapy is associated with longer overall survival in completely resected stage II and III thymoma -- an analysis of the International Thymic Malignancies Interest Group retrospective database." J Thorac Oncol. 2016;11(10):1785-1792.
• Loehrer PJ Sr et al. "Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial." J Clin Oncol. 1994;12(6):1164-1168.
• Jackson MW et al. "Post-operative radiotherapy for thymoma and thymic carcinoma." Cochrane Database Syst Rev. 2017.
• Girard N et al. "Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up." Ann Oncol. 2015;26(Suppl 5):v40-v55.

Read this lecture as Markdown